New phase III data on Takeda Pharmaceutical Co. Ltd.'s TAK-620 (maribavir) for the treatment of transplant recipients with tough-to-treat cytomegalovirus (CMV) infections met the trial's primary endpoint, setting the company up to file an NDA for the oral antiviral in the first half of next year.
HONG KONG and BEIJING – Hong Kong-listed China Grand Pharmaceutical and Healthcare Holdings Ltd. and Niel, Belgium-based mRNA vaccine specialist Etherna Immunotherapies NV are setting up a joint venture to develop, produce and commercialize mRNA prophylactic and therapeutic vaccines.
An international study led by Nanyang Technological University in Singapore has designed and synthesized broad-spectrum antimicrobial polymers (AMPs) and demonstrated the safety and efficacy of two such agents against multidrug-resistant (MDR) bacteria in mouse models of sepsis.
Researchers at the University of California at San Francisco have developed a method to diagnose any known pathogen from any body fluid within a day – or, depending on the sequencing method, within a few hours. For an unknown pathogen, the method spits out its nearest known relative.
Assembly Biosciences Inc., a company testing the limits of sustained virologic response in people with chronic hepatitis B virus infection after they discontinue treatment, said nearly all participants in an ongoing phase II study returned to having detectable viral loads after going off a regimen featuring the company's core inhibitor, vebicorvir.
It didn’t take long for a U.S. district judge to grant Gilead Sciences Inc.’s request for a temporary restraining order to stop two interconnected health care networks in Florida from defrauding the company’s Advancing Access Medication Assistance Program that provides free HIV pre-exposure prophylaxis drugs to eligible, uninsured people.
A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain.
DUBLIN – Kiadis Pharma BV has parlayed its €31.9 million (US$37.2 million) stock-based acquisition of Cytosen Therapeutics Inc. last year, which involved an initial outlay of just €14.5 million worth of shares, into a €308 million payday with Sanofi SA.
In Regeneron Pharmaceuticals Inc.’s Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), the FDA has approved its first ever treatment for the Ebola virus in pediatric and adult patients.
Monday, Oct. 5, was probably the first day of 2020 that SARS-CoV-2 had serious competition for science media attention – by another virus. The Nobel Assembly awarded the 2020 Nobel Prize for Physiology or Medicine to Harvey Alter, Michael Houghton and Charles Rice “for the discovery of hepatitis C virus.”
RSS
